Recent advances on biogenesis, functions and therapeutic potential of long noncoding RNAs in T cell acute lymphoblastic leukemia DOI Creative Commons
Parminder Kaur,

Pankaj Sharma,

Prateek Bhatia

et al.

Discover Oncology, Journal Year: 2024, Volume and Issue: 15(1)

Published: Nov. 29, 2024

T-cell Acute Lymphoblastic Leukemia (T-ALL) is a highly aggressive form of ALL with at least 25% relapse rates. The high rates are often linked to poor prognoses. More detailed studies for novel therapeutic targets the treatment T-ALL required as genetic and transcriptomic data currently available on pathophysiology insufficient. Long non-coding RNAs emerging important players in regulation tumour proliferation metastasis. Studies various cancers have revealed their potential biomarkers treatment. This review describes characterization, biosynthesis, role long RNA highlights next generation molecule development promising diagnostic, prognostic and/or markers.

Language: Английский

Targeting and engineering long non-coding RNAs for cancer therapy DOI
Michela Coan, Simon Haefliger,

Samir Ounzain

et al.

Nature Reviews Genetics, Journal Year: 2024, Volume and Issue: 25(8), P. 578 - 595

Published: Feb. 29, 2024

Language: Английский

Citations

68
The role of RNA methylation in tumor immunity and its potential in immunotherapy DOI Creative Commons
Yan Li,

Haoer Jin,

Qingling Li

et al.

Molecular Cancer, Journal Year: 2024, Volume and Issue: 23(1)

Published: June 20, 2024

Abstract RNA methylation, a prevalent post-transcriptional modification, has garnered considerable attention in research circles. It exerts regulatory control over diverse biological functions by modulating splicing, translation, transport, and stability. Notably, studies have illuminated the substantial impact of methylation on tumor immunity. The primary types encompass N6-methyladenosine (m6A), 5-methylcytosine (m5C), N1-methyladenosine (m1A), N7-methylguanosine (m7G), 3-methylcytidine (m3C). Compelling evidence underscores involvement regulating microenvironment (TME). By affecting translation stability through "writers", "erasers" "readers", influence dysregulation immune cells factors. Consequently, plays pivotal role immunity mediating various behaviors, encompassing proliferation, invasion, metastasis, etc. In this review, we discussed mechanisms several methylations, providing comprehensive overview their roles underlying within among immunocytes. exploring how these modifications mediate evasion, also examine potential applications immunotherapy. This review aims to provide novel insights strategies for identifying targets advancing cancer immunotherapy efficacy.

Language: Английский

Citations

32
Nucleic acid drugs: recent progress and future perspectives DOI Creative Commons

Xiaoyi Sun,

Sarra Setrerrahmane,

Chencheng Li

et al.

Signal Transduction and Targeted Therapy, Journal Year: 2024, Volume and Issue: 9(1)

Published: Nov. 29, 2024

Language: Английский

Citations

13
MALAT-1 Is a Key Regulator of Epithelial–Mesenchymal Transition in Cancer: A Potential Therapeutic Target for Metastasis DOI Open Access
Mohamed Ali Hussein,

Kamyab Valinezhad,

Eman Adel

et al.

Cancers, Journal Year: 2024, Volume and Issue: 16(1), P. 234 - 234

Published: Jan. 4, 2024

Metastasis-associated lung adenocarcinoma transcript-1 (MALAT-1) is a long intergenic non-coding RNA (lncRNA) located on chr11q13. It overexpressed in several cancers and controls gene expression through chromatin modification, transcriptional regulation, post-transcriptional regulation. Importantly, MALAT-1 stimulates cell proliferation, migration, metastasis serves vital role driving the epithelial-to-mesenchymal transition (EMT), subsequently acquiring cancer stem cell-like properties developing drug resistance. modulates EMT by interacting with various intracellular signaling pathways, notably phosphoinositide 3-kinase (PI3K)/Akt Wnt/β-catenin pathways. also behaves like sponge for microRNAs, preventing their interaction target genes promoting EMT. In addition, we have used bioinformatics online tools to highlight disparities of between normal samples using data from The Cancer Genome Atlas (TCGA). Furthermore, intricate interplay essential targets progression renders it good candidate therapeutic interventions. Several innovative approaches been exploited MALAT-1, such as short hairpin RNAs (shRNAs), antisense oligonucleotides (ASOs), natural products. This review emphasizes modulating metastasis, stemness, chemoresistance different cancers.

Language: Английский

Citations

12
M2 Tumor‐Associated Macrophages‐Derived Exosomal MALAT1 Promotes Glycolysis and Gastric Cancer Progression DOI
Yanzheng Wang, Jiahui Zhang, Hui Shi

et al.

Advanced Science, Journal Year: 2024, Volume and Issue: 11(24)

Published: April 19, 2024

Abstract M2‐polarized tumor‐associated macrophages (M2 TAMs) promote cancer progression. Exosomes mediate cellular communication in the tumor microenvironment (TME). However, roles of exosomes from M2 TAMs gastric progression are unclear. Herein, it is reported that TAMs‐derived induced aerobic glycolysis cells and enhanced their proliferation, metastasis, chemoresistance a glycolysis‐dependent manner. It identified MALAT1 (metastasis‐associated lung adenocarcinoma transcript 1) enriched TAM confirmed transfer to via mediates this effect. Mechanistically, interacted with δ‐catenin protein suppressed its ubiquitination degradation by β‐TRCP. In addition, upregulated HIF‐1α expression acting as sponge for miR‐217‐5p. The activation β‐catenin signaling pathways collectively led cells. Finally, dual‐targeted inhibition both exosome‐mediated delivery siRNA remarkably growth improved chemosensitivity mouse models. Taken together, these results suggest ‐mediated regulation glycolysis. findings offer potential target therapy.

Language: Английский

Citations

12
Therapeutic Antisense Oligonucleotides in Oncology: From Bench to Bedside DOI Open Access
Elif Çakan, Olivia D. Lara, Anna Szymanowska

et al.

Cancers, Journal Year: 2024, Volume and Issue: 16(17), P. 2940 - 2940

Published: Aug. 23, 2024

Advancements in our comprehension of tumor biology and chemoresistance have spurred the development treatments that precisely target specific molecules within body. Despite expanding landscape therapeutic options, there persists a demand for innovative approaches to address unmet clinical needs. RNA therapeutics emerged as promising frontier this realm, offering novel avenues intervention such interference utilization antisense oligonucleotides (ASOs). ASOs represent versatile class capable selectively targeting messenger RNAs (mRNAs) silencing disease-associated proteins, thereby disrupting pathogenic processes at molecular level. Recent advancements chemical modification carrier molecule design significantly enhanced stability, biodistribution, intracellular uptake ASOs, bolstering their potential. While ASO therapy holds promise across various disease domains, including oncology, coronary angioplasty, neurological disorders, viral, parasitic diseases, review manuscript focuses specifically on application targeted cancer therapies. Through comprehensive examination latest research findings developments, we delve into intricacies ASO-based treatment, shedding light mechanisms action, efficacy, prospects.

Language: Английский

Citations

7
Finding potential lncRNA–disease associations using a boosting-based ensemble learning model DOI Creative Commons
Liqian Zhou,

Xinhuai Peng,

Lijun Zeng

et al.

Frontiers in Genetics, Journal Year: 2024, Volume and Issue: 15

Published: March 1, 2024

Introduction: Long non-coding RNAs (lncRNAs) have been in the clinical use as potential prognostic biomarkers of various types cancer. Identifying associations between lncRNAs and diseases helps capture design efficient therapeutic options for diseases. Wet experiments identifying these are costly laborious. Methods: We developed LDA-SABC, a novel boosting-based framework lncRNA–disease association (LDA) prediction. LDA-SABC extracts LDA features based on singular value decomposition (SVD) classifies pairs (LDPs) by incorporating LightGBM AdaBoost into convolutional neural network. Results: The performance was evaluated under five-fold cross validations (CVs) lncRNAs, diseases, LDPs. It obviously outperformed four other classical inference methods (SDLDA, LDNFSGB, LDASR, IPCAF) through precision, recall, accuracy, F1 score, AUC, AUPR. Based accurate prediction we used it to find lncRNA lung results elucidated that 7SK HULC could relationship with non-small-cell cancer (NSCLC) adenocarcinoma (LUAD), respectively. Conclusion: hope our proposed method can help improve identification.

Language: Английский

Citations

6
Long Non-Coding RNAs as Regulators for Targeting Breast Cancer Stem Cells and Tumor Immune Microenvironment: Biological Properties and Therapeutic Potential DOI Open Access
Fang Yang, Y L Yang, Yuling Qiu

et al.

Cancers, Journal Year: 2024, Volume and Issue: 16(2), P. 290 - 290

Published: Jan. 10, 2024

Breast cancer stem cells (BCSCs) is a subpopulation of with self-renewal and differentiation capacity, have been suggested to give rise tumor heterogeneity biologically aggressive behavior. Accumulating evidence has shown that BCSCs play fundamental role in tumorigenesis, progression, recurrence. The development immunotherapy, primarily represented by programmed cell death protein 1 (PD-1)/programmed death-ligand (PD-L1) inhibitors, greatly changed the treatment landscape multiple malignancies. Recent studies identified pervasive negative associations between stemness anticancer immunity. Stemness seems causative formation cold immune microenvironment (TIME). functions long non-coding RNAs (lncRNAs) regulating responses recently highlighted breast cancer. review focus on lncRNAs keys pathways involved regulation TIME. Potential clinical applications using as biomarkers or therapies will be discussed.

Language: Английский

Citations

4
MDSCs in bone metastasis: Mechanisms and therapeutic potential DOI
Zhi Li,

Qi Xia,

Yujie He

et al.

Cancer Letters, Journal Year: 2024, Volume and Issue: 592, P. 216906 - 216906

Published: April 21, 2024

Language: Английский

Citations

4
LncRNA in gastric cancer drug resistance: deciphering the therapeutic strategies DOI Creative Commons

Weiling Liu,

WeiFa Wang

Frontiers in Oncology, Journal Year: 2025, Volume and Issue: 15

Published: April 1, 2025

Gastric cancer (GC) is an exceedingly aggressive disease and ranks as the third leading cause of cancer-related deaths, which poses a huge health burden globally. Chemotherapy commonly employed during middle to advanced stages cancer, although it faces frequent treatment failures attributed drug resistance. Thus, imperative for researchers identify potential targets overcoming therapeutic resistance, thereby facilitating development novel anti-cancer agents GC patients with stages. Long noncoding RNAs (lncRNAs) are diverse group transcripts limited protein-coding capacity, have been recognized functional molecules regulating progression including cell proliferation, metastasis, resistance in GC. In this review, we examine intricate molecular networks on role lncRNAs LncRNAs conferred through various mechanisms, therefore functioning promising patients. Additionally, discuss current advancements strategies targeting therapy, may pave way lncRNA-mediated precision medicine malignant disease.

Language: Английский

Citations

0